{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:03Z","timestamp":1792931943838,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (<jats:italic>n<\/jats:italic>\u2009=\u2009404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782\u20131.408; two-sided <jats:italic>p<\/jats:italic>\u2009=\u20090.749) and non-intensive (<jats:italic>n<\/jats:italic>\u2009=\u2009325; HR 0.99; 95% CI: 0.768\u20131.289; two-sided <jats:italic>p<\/jats:italic>\u2009=\u20090.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration<jats:bold>:<\/jats:bold> ClinicalTrials.gov: NCT03416179.<\/jats:p>","DOI":"10.1038\/s41375-023-02001-z","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T18:02:39Z","timestamp":1692640959000},"page":"2017-2026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-0973","authenticated-orcid":false,"given":"Benjamin","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-822X","authenticated-orcid":false,"given":"Akil","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whijae","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine G.","family":"DiRienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2001_CR1","unstructured":"NIH National Cancer Institute. Surveillance, Epidemiology and End Results Program (SEER). Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML). (Last Update 2022). https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"2001_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458.","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127:2049\u201361. https:\/\/doi.org\/10.1002\/cncr.33458.","journal-title":"Cancer."},{"key":"2001_CR3","doi-asserted-by":"publisher","unstructured":"de Leeuw DC, Ossenkoppele GJ, Janssen J. Older patients with acute myeloid leukemia deserve individualized treatment. Curr Oncol Rep. 2022. https:\/\/doi.org\/10.1007\/s11912-022-01299-9.","DOI":"10.1007\/s11912-022-01299-9"},{"key":"2001_CR4","doi-asserted-by":"publisher","unstructured":"Potenza L, Borelli E, Bigi S, Giusti D, Longo G, Odejide O, et al. Early palliative care in acute myeloid leukemia. Cancers. 2022; 14. https:\/\/doi.org\/10.3390\/cancers14030478.","DOI":"10.3390\/cancers14030478"},{"key":"2001_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/sj.leu.2403289.","volume":"18","author":"MA Sekeres","year":"2004","unstructured":"Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18:809\u201316. https:\/\/doi.org\/10.1038\/sj.leu.2403289.","journal-title":"Leukemia"},{"key":"2001_CR6","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920.","volume":"4","author":"MA Sekeres","year":"2020","unstructured":"Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4:3528\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2020001920.","journal-title":"Blood Adv"},{"key":"2001_CR7","unstructured":"American Cancer Society (ACS). Chemotherapy for Acute Myeloid Leukemia (AML). 2020 (Last Update 03 September 2020). https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/treating\/chemotherapy.html."},{"key":"2001_CR8","first-page":"S347","volume":"24","author":"M Wiese","year":"2018","unstructured":"Wiese M, Daver N. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care. 2018;24:S347\u2013s355.","journal-title":"Am J Manag Care"},{"key":"2001_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214.","volume":"93","author":"EH Estey","year":"2018","unstructured":"Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93:1267\u201391. https:\/\/doi.org\/10.1002\/ajh.25214.","journal-title":"Am J Hematol"},{"key":"2001_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196.","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"2001_CR11","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/jco.2011.38.9429.","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137. https:\/\/doi.org\/10.1200\/jco.2011.38.9429.","journal-title":"J Clin Oncol"},{"key":"2001_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496.","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114\u201324. https:\/\/doi.org\/10.1002\/cncr.22496.","journal-title":"Cancer"},{"key":"2001_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2011.59.","volume":"25","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia. 2011;25:1122\u20137. https:\/\/doi.org\/10.1038\/leu.2011.59.","journal-title":"Leukemia"},{"key":"2001_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557.","volume":"124","author":"H D\u00f6hner","year":"2014","unstructured":"D\u00f6hner H, L\u00fcbbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426\u201333. https:\/\/doi.org\/10.1182\/blood-2014-03-560557.","journal-title":"Blood"},{"key":"2001_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664.","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291\u20139. https:\/\/doi.org\/10.1182\/blood-2015-01-621664.","journal-title":"Blood"},{"key":"2001_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s1470-2045(18)30010-x.","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328. https:\/\/doi.org\/10.1016\/s1470-2045(18)30010-x.","journal-title":"Lancet Oncol"},{"key":"2001_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971.","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"2001_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3324\/haematol.2019.236992.","volume":"106","author":"A Chaturvedi","year":"2021","unstructured":"Chaturvedi A, Gupta C, Gabdoulline R, Borchert NM, Goparaju R, Kaulfuss S, et al. Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Haematologica. 2021;106:565\u201373. https:\/\/doi.org\/10.3324\/haematol.2019.236992.","journal-title":"Haematologica"},{"key":"2001_CR19","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752.","volume":"119","author":"DA Irvine","year":"2012","unstructured":"Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 2012;119:2196\u2013204. https:\/\/doi.org\/10.1182\/blood-2011-10-383752.","journal-title":"Blood"},{"key":"2001_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/ml2002423.","volume":"3","author":"MJ Munchhof","year":"2012","unstructured":"Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett. 2012;3:106\u201311. https:\/\/doi.org\/10.1021\/ml2002423.","journal-title":"ACS Med Chem Lett"},{"key":"2001_CR21","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Daurismo (glasdegib). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210656s000lbl.pdf. Accessed 16 August 2023."},{"key":"2001_CR22","unstructured":"European Medicines Agency. Summary of product characteristics: Daurismo (glasdegib). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/daurismo-epar-product-information_en.pdf. Accessed 16 August 2023."},{"key":"2001_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9.","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379\u201389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9.","journal-title":"Leukemia"},{"key":"2001_CR24","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.2217\/fon-2019-0373.","volume":"15","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, et al. Glasdegib plus intensive\/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019;15:3531\u201345. https:\/\/doi.org\/10.2217\/fon-2019-0373.","journal-title":"Future Oncol"},{"key":"2001_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544.","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"key":"2001_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544.","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249\u201359. https:\/\/doi.org\/10.1056\/NEJMoa0904544.","journal-title":"N Engl J Med"},{"key":"2001_CR27","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409.","volume":"361","author":"B Lowenberg","year":"2009","unstructured":"Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235\u201348. https:\/\/doi.org\/10.1056\/NEJMoa0901409.","journal-title":"N Engl J Med"},{"key":"2001_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-20-0007.","volume":"1","author":"C Jamieson","year":"2020","unstructured":"Jamieson C, Martinelli G, Papayannidis C, Cortes JE. Hedgehog pathway inhibitors: a new therapeutic class for the treatment of acute myeloid leukemia. Blood Cancer Discov. 2020;1:134\u201345. https:\/\/doi.org\/10.1158\/2643-3230.BCD-20-0007.","journal-title":"Blood Cancer Discov"},{"key":"2001_CR29","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.febslet.2012.05.011.","volume":"586","author":"D Javelaud","year":"2012","unstructured":"Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS Lett. 2012;586:2016\u201325. https:\/\/doi.org\/10.1016\/j.febslet.2012.05.011.","journal-title":"FEBS Lett"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02001-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02001-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02001-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:03:58Z","timestamp":1696943038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02001-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02001-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mikkael A. Sekeres holds a consulting or advisory role with Celgene, Millennium, and Syros Pharmaceuticals and received research funding from Pfizer and Takeda. Pau Montesinos is a consultant to, has received research funding from, and is on the speakers\u2019 bureau for AbbVie, Bristol Meyers Squibb, and Pfizer; he is a consultant to and has received research funding from Menarini\/Stemline, Novartis, and Takeda; he is a consultant to and on the speakers\u2019 bureau for Jazz Pharmaceuticals and Astellas; and he\u00a0is a consultant to Otsuka, Kura Oncology, Beigene, Incyte, Ryvu, and Nerviano. Jan Novak has a consulting or advisory role with Amgen, Takeda, Roche, Celgene, Pfizer, and Novartis and has received travel accommodations from Amgen and Janssen. Jianxiang Wang has an advisory role with honoraria for AbbVie. Deepa Jeyakumar received research funding from Pfizer and Jazz Pharmaceuticals. Benjamin Tomlinson and Erin Jou: nothing to disclose. David C. Taussig is supported by the National Institute for Health and Care Research (NICR) Royal Marsden\/Institute of Cancer Research Biomedical Research Centre. Jiri Mayer reports research funding from AbbVie. Tadeusz Robak receives honoraria from AstraZeneca and Janssen and has a consultancy or advisory role and received research funding from Acerta, AstraZeneca, and Janssen. Herv\u00e9 Dombret received honoraria or consulting fees from AbbVie, Amgen, Astellas, Celgene-BMS, Daiichi Sankyo, Incyte, Jazz Pharmaceuticals, Pfizer, and Servier and research funding from Amgen, Astellas, Celgene-Bristol Meyers Squibb, Incyte, Jazz Pharmaceuticals, and Pfizer. Akil Merchant serves on the advisory boards of Agios, Pfizer, and Takeda and received research funding from Pfizer. Naveed Shaik, Thomas O'Brien, Whijae Roh, Xueli Liu, Wendy Ma, Christine G. DiRenzo, and Geoffrey Chan are current or former employees of Pfizer and may hold stock ownership in Pfizer. Jorge E. Cortes has a consulting or advisory role with Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BioLineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda and received research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Trovagene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}